Coagulation Biomarkers and Clinical Outcomes in Elderly Patients With Nonvalvular Atrial Fibrillation

[1]  S. Halvorsen,et al.  Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation , 2021, Heart.

[2]  W. Shimizu,et al.  Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry , 2021, European heart journal. Quality of care & clinical outcomes.

[3]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[4]  Kazuhiro Tada,et al.  Residual risks of ischaemic stroke and systemic embolism among atrial fibrillation patients with anticoagulation: large-scale real-world data (F-CREATE project) , 2020, Heart.

[5]  E. Stecker,et al.  Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges , 2020, Journal of the American Heart Association.

[6]  J. Schefold,et al.  Renal Function-Adjusted D-Dimer Levels in Critically Ill Patients With Suspected Thromboembolism. , 2020, Critical care medicine.

[7]  O. Oladiran,et al.  Stroke risk stratification in atrial fibrillation: a review of common risk factors , 2019, Journal of community hospital internal medicine perspectives.

[8]  M. Ebell.  Evaluating Benefits and Harms of Anticoagulation in Patients with Atrial Fibrillation. , 2018, American Family Physician.

[9]  K. Kario,et al.  Prospective observational study in elderly patients with non-valvular atrial fibrillation: Rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry. , 2018, Journal of cardiology.

[10]  R. de Caterina,et al.  Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation , 2018, Heart.

[11]  K. Mahaffey,et al.  2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. , 2017, Journal of the American College of Cardiology.

[12]  E. Antman,et al.  Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. , 2016, JAMA cardiology.

[13]  K. Prodanova,et al.  Early Changes in the Antithrombin and Thrombin-Antithrombin Complex in Patients With Paroxysmal Atrial Fibrillation , 2016, Cardiology research.

[14]  M. Ieko,et al.  Profiles of direct oral anticoagulants and clinical usage—dosage and dose regimen differences , 2016, Journal of Intensive Care.

[15]  Claes Held,et al.  The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation , 2016, European heart journal.

[16]  G. Lip,et al.  Stroke and Major Bleeding Risk in Elderly Patients Aged ≥75 Years With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project , 2015, Stroke.

[17]  E. Hylek,et al.  D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial , 2014, Journal of thrombosis and haemostasis : JTH.

[18]  G. Lippi,et al.  Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence , 2014, Annals of medicine.

[19]  A. Exadaktylos,et al.  D-dimer to rule out pulmonary embolism in renal insufficiency. , 2014, The American journal of medicine.

[20]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[21]  D. Atar,et al.  High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. , 2014, Journal of the American College of Cardiology.

[22]  D. Atar,et al.  High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial , 2013, Circulation.

[23]  S. Hohnloser,et al.  N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). , 2013, Journal of the American College of Cardiology.

[24]  P. Sanders,et al.  Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. , 2013, Journal of the American College of Cardiology.

[25]  M. Yılmaz,et al.  Increased d-dimer levels predict cardiovascular mortality in patients with systolic heart failure , 2012, Journal of Thrombosis and Thrombolysis.

[26]  S. Yusuf,et al.  Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy , 2012, Circulation.

[27]  A. Abdelhafiz,et al.  Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach. , 2012, Aging and disease.

[28]  S. Ogawa,et al.  Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. , 2010, Journal of the American College of Cardiology.

[29]  A. Iwasa,et al.  Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation. , 2008, International journal of cardiology.

[30]  A. Iwasa,et al.  D-dimer level influences thromboembolic events in patients with atrial fibrillation. , 2006, International journal of cardiology.